Martine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock
Martine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $259.60, for a total value of $2,076,800.00. Following the sale, the chief executive officer now owns 130 shares of the company's stock, valued at approximately $33,748. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
聯合治療公司(納斯達克：UTHR-GET評級)首席執行官馬丁·A·羅斯布拉特在1月19日星期四的一筆交易中出售了8,000股該公司股票。這些股票的平均價格為259.60美元，總價值為2,076,800.00美元。出售後，首席執行官現在擁有130股公司股票，價值約33,748美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可以通過這個環節.
United Therapeutics Stock Up 0.6 %
聯合治療公司股票上漲0.6%
Shares of United Therapeutics stock opened at $261.70 on Friday. The business's fifty day moving average price is $270.84 and its two-hundred day moving average price is $241.25. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. The company has a market capitalization of $11.93 billion, a P/E ratio of 17.80, a PEG ratio of 1.54 and a beta of 0.62. United Therapeutics Co. has a 1-year low of $158.38 and a 1-year high of $283.09.
聯合治療公司的股票週五開盤報261.70美元。該業務的50日移動均線價格為270.84美元，200日移動均線價格為241.25美元。該公司的債務權益比為0.18，流動比率為9.68，速動比率為9.39。該公司市值為119.3億美元，市盈率為17.80倍，聚乙二醇率為1.54倍，貝塔係數為0.62。聯合治療公司股價跌至158.38美元的一年低點和283.09美元的一年高點。
United Therapeutics (NASDAQ:UTHR – Get Rating) last announced its earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, beating the consensus estimate of $3.57 by $1.34. The firm had revenue of $516.00 million for the quarter, compared to the consensus estimate of $492.92 million. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. As a group, research analysts forecast that United Therapeutics Co. will post 16.63 EPS for the current year.
聯合治療公司(納斯達克：UTHR-GET評級)最近一次公佈收益結果是在11月2日星期三。這家生物技術公司公佈本季度每股收益為4.91美元，比普遍預期的3.57美元高出1.34美元。該公司本季度營收為5.16億美元，而市場普遍預期為4.9292億美元。聯合治療公司的股本回報率為16.63%，淨利潤率為38.03%。作為一個整體，研究分析師預測，聯合治療公司本年度的每股收益將達到16.63美元。
Institutional Trading of United Therapeutics
聯合治療公司的制度性交易
Analyst Ratings Changes
分析師評級發生變化
Several brokerages have recently commented on UTHR. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, November 3rd. Wedbush lifted their target price on United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. HC Wainwright lifted their target price on United Therapeutics from $255.00 to $300.00 and gave the stock a "buy" rating in a research report on Thursday, November 3rd. Oppenheimer lifted their target price on United Therapeutics from $325.00 to $375.00 and gave the stock an "outperform" rating in a research report on Thursday, November 3rd. Finally, JPMorgan Chase & Co. lifted their target price on United Therapeutics from $240.00 to $265.00 and gave the stock an "overweight" rating in a research report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $283.64.
幾家券商最近對UTHR發表了評論。在11月3日星期四的一份研究報告中，StockNews.com將聯合治療公司的評級從“買入”上調至“強力買入”。韋德布什在11月3日星期四的一份研究報告中將他們對聯合治療公司的目標價從250.00美元上調至305.00美元。11月3日週四，在一份研究報告中，HC Wainwright將聯合治療公司的目標價從255.00美元上調至300.00美元，並給予該股“買入”評級。奧本海默將聯合治療公司的目標價從325.00美元上調至375.00美元，並在11月3日週四的一份研究報告中給出了該股的“跑贏大盤”評級。最終，摩根大通將聯合治療公司的目標價從240.00美元上調至265.00美元，並在11月3日週四的一份研究報告中給予該股“增持”評級。兩名分析師對該股的評級為賣出，一名分析師給予持有評級，九名分析師給予買入評級，一名分析師對該股給予強烈買入評級。根據MarketBeat的數據，該公司的平均評級為“適度買入”，共識目標價為283.64美元。
About United Therapeutics
關於聯合治療公司
(Get Rating)
(獲取評級)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
聯合治療公司是一家生物技術公司，致力於產品的開發和商業化，以滿足美國和國際上慢性和危及生命的疾病患者未得到滿足的醫療需求。其商業療法包括用於治療肺動脈高壓(PAH)患者的Remodlin，以減輕運動相關症狀；TYVASO，一種前列環素類似物Treprostinil的吸入製劑，用於增強PAH患者的運動能力；Treprostinil的片劑Orenitram，用於增強PAH患者的運動能力；Unitusin，用於治療高危神經母細胞瘤；以及AdCirca，口服PDE-5抑制劑，用於增強PAH患者的運動能力。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免費獲取StockNews.com關於聯合治療(UTHR)的研究報告
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車？
- 諾德斯特龍對零售業降價的擔憂
- 埃克森美孚股票：在Buy Point附近
- 高股息率的必和必拓認為中國推動了23年的增長
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受聯合治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對聯合治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。